Research programme: SLC13A5 protein inhibitors - Eternygen/EvotecAlternative Names: NaCT inhibitors - Eternygen/Evotec
Latest Information Update: 08 May 2014
At a glance
- Originator Eternygen; Evotec AG
- Class Small molecules
- Mechanism of Action SLC13A5 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Metabolic disorders
Most Recent Events
- 06 May 2014 Early research in Metabolic disorders in Germany (unspecified route)